Cargando…

Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19”

Detalles Bibliográficos
Autores principales:	Mastellos, Dimitrios C., Lambris, John D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585627/ https://www.ncbi.nlm.nih.gov/pubmed/33115645 http://dx.doi.org/10.1016/j.clim.2020.108617

Ejemplares similares

Commentary on “Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al.
por: de Miranda Santos, Isabel Kinney Ferreira, et al.
Publicado: (2021)

Efficacy matters: broadening complement inhibition in COVID-19
por: Mastellos, Dimitrios C, et al.
Publicado: (2021)

Complement as a target in COVID-19?
por: Risitano, Antonio M., et al.
Publicado: (2020)

Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads
por: Mastellos, Dimitrios C., et al.
Publicado: (2020)

Comment on Havens and colleagues (2019)
por: Hinz, Hariet L, et al.
Publicado: (2019)

Response to Damiani and colleagues
por: Diehl, J-L, et al.
Publicado: (2020)

Author Correction: Complement as a target in COVID-19?
por: Risitano, Antonio M., et al.
Publicado: (2020)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

Response to letter by Prof Christian Nolte and colleagues
por: Dawson, Jesse, et al.
Publicado: (2022)

Response to comments on our article (Yin YL et al., Parasit Vectors, 10.1186/s13071-021-04739-w) by Yuqing Wang and colleagues
por: Yin, Yan-Ling, et al.
Publicado: (2021)

Comment to the article: “Consensus statement on the definition of orthostatic hypertension endorsed by the American Autonomic Society and the Japanese Society of Hypertension” by Jordan and colleagues
por: Moreno Velásquez, Ilais, et al.
Publicado: (2022)

Stigma related to COVID-19 infection: Are the Health Care Workers stigmatizing their own colleagues?
por: Grover, Sandeep, et al.
Publicado: (2020)

How Political Science Can Contribute to Public Health: A Response to Gagnon and Colleagues
por: Kothari, Anita, et al.
Publicado: (2017)

Complement-Dependent Mechanisms and Interventions in Periodontal Disease
por: Hajishengallis, George, et al.
Publicado: (2019)

Should we avoid colleagues in leisure time during the coronavirus disease 2019 (COVID-19) pandemic?
por: Oksanen, Lotta-Maria A. H., et al.
Publicado: (2020)

Authors’ reply to Quantrill, Benger, Ripley and colleagues, Roach, Rogers, and Haldar and colleagues
por: Wiener, Renda Soylemez, et al.
Publicado: (2013)

Physical activity and sedentary behaviour typologies of 10-11 year olds - Response to Saunders and Colleagues
por: Jago, Russell, et al.
Publicado: (2011)

Oestrogen receptors in primary breast cancer: Dr. Alanko and colleagues reply
por: Alanko, A., et al.
Publicado: (1985)

Lymphoid infiltration and prognosis in colorectal carcinoma: Dr. Sevennevig & Colleagues reply
por: Svennevig, J.L., et al.
Publicado: (1984)

Document for patient's sake.... for your colleague's sake! Document.... for GOD'S sake!!
por: Chhabra, Swati, et al.
Publicado: (2018)

Response to the letter to the Editor “Comparing video and direct laryngoscopy for tracheal intubation in the general ward” by Shao and Colleagues
por: Baek, Moon Seong, et al.
Publicado: (2019)

REPLY: Reply to Kumar and colleagues
por: Kirklin, James K.
Publicado: (2022)

Young colleagues need support
por: Landes, D. P.
Publicado: (2020)

Reply to the Letter to Editor by Lacout and colleagues: Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis
por: Prasad, Manya, et al.
Publicado: (2021)

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
por: Mastaglio, Sara, et al.
Publicado: (2020)

In Vivo Role of Complement-Interacting Domains of Herpes Simplex Virus Type 1 Glycoprotein Gc
por: Lubinski, John, et al.
Publicado: (1999)

Potential Role of Anti-Complement Agents in the Treatment of COVID-19-Related ARDS
por: Spanopoulou, Christina, et al.
Publicado: (2020)

Dear Authors and Colleagues
por: Baek, Moo-Jun
Publicado: (2020)

Commenting on “Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from ACE 2 study” by Jacob A. Winther and colleagues
por: Castello, Luigi Mario, et al.
Publicado: (2018)

Comment on: “Pharmaco-Immunomodulatory Therapy in COVID-19”
por: Vrachatis, Dimitrios A., et al.
Publicado: (2020)

Pulmonary metastasectomy in colorectal cancer: A letter in response to Antonoff and colleagues
por: Macbeth, Fergus, et al.
Publicado: (2021)

Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics
por: Gavriilaki, Eleni, et al.
Publicado: (2019)

Complement activation in patients with COVID-19: A novel therapeutic target
por: Cugno, Massimo, et al.
Publicado: (2020)

Complement C5 inhibition in patients with COVID- 19 - a promising target?
por: de Latour, Regis Peffault, et al.
Publicado: (2020)

Comment on “Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?”
por: Cure, Erkan, et al.
Publicado: (2020)

Increased prevalence of VTE reported by Klok and colleagues, the numbers don't add up
por: Greenstein, Yonatan Y.
Publicado: (2020)

Climate and clean air responses to COVID-19: a comment
por: Arafat, S. M. Yasir, et al.
Publicado: (2020)

Response to comments on: Rise of the phoenix: Mucormycosis in COVID-19 times
por: Ravani, Swati A, et al.
Publicado: (2021)

Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment
por: Jin, Tianru, et al.
Publicado: (2020)

Response comment on: Retinal manifestations in patients following COVID-19 infection
por: Goyal, Mallika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lar45d65ic6bk31797nrdv93he